EGFR and non-small cell lung carcinoma: Although EGFR positive patients were included in IMpower010, given the results of the ADAURA study and questionable benefit of ICIs in later line treatment of EGFR positive NSCLC, it is likely that most clinicians will opt for adjuvant osimertinib in these patients.